Molecular Insight Pharmaceuticals, which is developing radiopharmaceuticals to treat cancer and targeted diagnostic tests, priced its initial public offering of 5 million shares at $14, the low end of its proposed $14 to $16 range, on Thursday night. RBC Capital Market and Jefferies were the joint book runners on the deal. The stock is expected to begin trading on the NASDAQ under the ticker MIPI on Friday.
